Capivasertib delays disease progression
Nature Reviews Clinical Oncology, Published online: 13 June 2023; doi:10.1038/s41571-023-00790-xCapivasertib delays disease progression (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 13, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Adjuvant osimertinib improves overall survival
Nature Reviews Clinical Oncology, Published online: 13 June 2023; doi:10.1038/s41571-023-00791-wAdjuvant osimertinib improves overall survival (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 13, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Second-line axi-cel improves overall survival
Nature Reviews Clinical Oncology, Published online: 13 June 2023; doi:10.1038/s41571-023-00793-8Second-line axi-cel improves overall survival (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 13, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Nature Reviews Clinical Oncology, Published online: 09 June 2023; doi:10.1038/s41571-023-00783-wAdvances in technology have enabled the development of several novel antibody–drug conjugates (ADCs) with encouraging clinical activity in patients with advanced-stage solid tumours. Indications for these therapies are expanding rapidly to earlier lines of therapy. Nonetheless, the toxicities of these various agents are not trivial and can be fatal, even in patients with early stage disease. In this Review, the authors summarize the toxicities of ADCs in patients with solid tumours both as monotherapies and in combination with...
Source: Nature Reviews Clinical Oncology - June 9, 2023 Category: Cancer & Oncology Authors: Paolo Tarantino Biagio Ricciuti Shan M. Pradhan Sara M. Tolaney Source Type: research
Emerging evidence for adapting radiotherapy to immunotherapy
Nature Reviews Clinical Oncology, Published online: 06 June 2023; doi:10.1038/s41571-023-00782-xRadiotherapy has several key attributes that make it an attractive combination partner for immunotherapy; however, numerous clinical trials investigating the combination of these two treatment modalities have failed to demonstrate clear improvements in patient outcomes. In this Review, Galluzzi and colleagues discuss the evidence indicating that radiotherapy administered according to standard schedules and target volumes might impair immune fitness and, therefore, propose that adaptation of the radiotherapy regimens to immunothe...
Source: Nature Reviews Clinical Oncology - June 6, 2023 Category: Cancer & Oncology Authors: Lorenzo Galluzzi Molykutty J. Aryankalayil C. Norman Coleman Silvia C. Formenti Source Type: research
Circulating tumour cells for early detection of clinically relevant cancer
Nature Reviews Clinical Oncology, Published online: 02 June 2023; doi:10.1038/s41571-023-00781-yThe authors of this Perspective propose that, with further improvement in detection efficiency, circulating tumour cells (CTCs), which are released early during cancer development, have the potential to be used for the early detection of clinically relevant, aggressive cancers. Thus, use of CTCs as diagnostic biomarkers might improve outcomes by enabling the identification of cancers at a stage at which they are more amenable to treatment while avoiding overtreatment of patients with indolent tumours. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 2, 2023 Category: Cancer & Oncology Authors: Rachel Lawrence Melissa Watters Caitlin R. Davies Klaus Pantel Yong-Jie Lu Source Type: research
Early stage gastric adenocarcinoma: clinical and molecular landscapes
Nature Reviews Clinical Oncology, Published online: 01 June 2023; doi:10.1038/s41571-023-00767-wLong-term survival rates of patients with gastric cancer remain low, particularly in Western countries. This lack of progress, among other aspects, is likely to reflect a focus on empirical approaches that fail to account for the heterogeneity of gastric cancers. In this Review, the authors summarize the available evidence on the management of patients with early stage gastric cancers, with an emphasis on understanding the underlying biology in order to improve the outcomes in patients with these historically difficult-to-treat ...
Source: Nature Reviews Clinical Oncology - June 1, 2023 Category: Cancer & Oncology Authors: Yuki Hirata Ayesha Noorani Shumei Song Linghua Wang Jaffer A. Ajani Source Type: research
The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?
Nature Reviews Clinical Oncology, Published online: 31 May 2023; doi:10.1038/s41571-023-00788-5The FDA Accelerated Approval pathway, which has been pivotal in enabling early access to new oncology drugs over the past three decades, has recently come under increased scrutiny. New draft guidance published in March 2023 offers several possible solutions to improve this pathway, with the ultimate goal of improving outcomes for patients with cancer, but might also have important limitations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 31, 2023 Category: Cancer & Oncology Authors: David J. Benjamin Mark P. Lythgoe Source Type: research
Newly diagnosed AML: quizartinib improves OS
Nature Reviews Clinical Oncology, Published online: 30 May 2023; doi:10.1038/s41571-023-00787-6Newly diagnosed AML: quizartinib improves OS (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 30, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL
Nature Reviews Clinical Oncology, Published online: 26 May 2023; doi:10.1038/s41571-023-00786-7Venetoclax–obinutuzumab combinations are effective in fit patients with CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 26, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Nature Reviews Clinical Oncology, Published online: 25 May 2023; doi:10.1038/s41571-023-00776-9The effective management of treatment-related events remains an unmet need in oncology. The authors of this Review discuss the underlying biological mechanisms, risk factors, most commonly used pharmacological and non-pharmacological management strategies, and clinical practice guidelines for the most common long-term (continuing beyond treatment) and late or delayed (following treatment) adverse events associated with chemotherapy and other anticancer treatments. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 25, 2023 Category: Cancer & Oncology Authors: Maryam B. Lustberg Nicole M. Kuderer Aakash Desai Cristiane Bergerot Gary H. Lyman Source Type: research
The roles and implications of RNA m6A modification in cancer
Nature Reviews Clinical Oncology, Published online: 23 May 2023; doi:10.1038/s41571-023-00774-xDysregulation of N6-methyladenosine (m6A), the most prevalent internal modification in eukaryotic mRNA, is common in various cancer types. The authors of this Review provide an overview of the mechanisms of m6A-dependent RNA regulation, summarize current knowledge of their pathological effects and potential utility as biomarkers in cancer, and describe ongoing efforts to develop small-molecule inhibitors of oncogenic m6A modifiers. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 23, 2023 Category: Cancer & Oncology Authors: Xiaolan Deng Ying Qing David Horne Huilin Huang Jianjun Chen Source Type: research
SUNLIGHT illuminates the activity of bevacizumab
Nature Reviews Clinical Oncology, Published online: 17 May 2023; doi:10.1038/s41571-023-00784-9SUNLIGHT illuminates the activity of bevacizumab (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 17, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Nature Reviews Clinical Oncology, Published online: 15 May 2023; doi:10.1038/s41571-023-00770-1Cholangiocarcinoma is a malignancy that continues to be associated with a dismal prognosis, and a better understanding of the disease biology is required to improve early detection and treatment strategies. In this Review, the authors describe key scientific and clinical advances made in this area over the past 5 years, encompassing novel insights into the tumour stroma and immune microenvironment, promising progress in developing liquid biopsy approaches for diagnosis and monitoring, clinical translation of molecularly targeted ...
Source: Nature Reviews Clinical Oncology - May 15, 2023 Category: Cancer & Oncology Authors: Sumera I. Ilyas Silvia Affo Lipika Goyal Angela Lamarca Gonzalo Sapisochin Ju Dong Yang Gregory J. Gores Source Type: research
National value-based pricing negotiation for oncology drugs — lessons from China
Nature Reviews Clinical Oncology, Published online: 12 May 2023; doi:10.1038/s41571-023-00769-8Between 2016 and 2022, 83 previously approved oncology drugs were covered and reimbursed in China through a value-based pricing negotiation programme, which resulted in substantial price cuts but did not improve the correlation between drug cost and clinical benefit. Herein, we call for an improved, transparent value-based pricing model to better account for high-value innovation in oncology drugs. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 12, 2023 Category: Cancer & Oncology Authors: Jing Yuan Minghui Li Z. Kevin Lu Source Type: research
